Infantile hemangiomas (IHs) occur in as many as 5% of infants, making
them the most common benign tumour of infancy. Most IHs are small, innocuous, self-resolving, and require no treatment. However, because of their
size or location, a significant minority of IHs are potentially problematic. This clinical practice guideline, published recently in Pediatrics
, defines those IHs that are potentially higher risk and discusses their specific growth characteristics. Early intervention (ideally by
1 month of age) is recommended. When systemic treatment is indicated, propranolol is the drug of choice. Topical timolol may be used to treat select
small, thin, superficial IHs. Surgery and/or laser treatment are most useful for the treatment of residual skin changes after involution.
Read 'Abridged Cochrane systematic review and GRADE assessments for IHs'